GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Development services for gene and cell therapies is planned to begin first in 2025
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Receives registration of Valganciclovir powder for oral solution in Germany
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
General Medicine grows 5% and Vaccines 10% led by Shingrix
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Subscribe To Our Newsletter & Stay Updated
